Synthetic catalytic scavenger - Eukarion/IsoTis

Drug Profile

Synthetic catalytic scavenger - Eukarion/IsoTis

Alternative Names: Oxyscav; Reactive oxygen species scavenger - Eukarion/IsoTis

Latest Information Update: 15 Jan 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eukarion
  • Developer IsoTis SA
  • Class Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Radiation-induced skin damage

Most Recent Events

  • 08 Jan 2003 Modex Therapeutics has merged with IsoTis NV to form IsoTis SA
  • 07 Jan 2003 Discontinued - Preclinical for Radiation-induced skin damage in USA (Topical)
  • 17 Jan 2002 Modex Therapeutics has submitted a pre-IND package to the US FDA for Oxyscav in patients with breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top